Kingswood Wealth Advisors LLC Sells 5,873 Shares of Eli Lilly and Company (NYSE:LLY)

Kingswood Wealth Advisors LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 40.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 8,757 shares of the company’s stock after selling 5,873 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $6,761,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Register Financial Advisors LLC boosted its position in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Register Financial Advisors LLC now owns 1,190 shares of the company’s stock valued at $919,000 after acquiring an additional 20 shares in the last quarter. PFG Investments LLC boosted its position in Eli Lilly and Company by 16.7% in the fourth quarter. PFG Investments LLC now owns 8,834 shares of the company’s stock valued at $6,820,000 after buying an additional 1,262 shares in the last quarter. Strategic Investment Advisors MI boosted its position in Eli Lilly and Company by 5.5% in the fourth quarter. Strategic Investment Advisors MI now owns 2,581 shares of the company’s stock valued at $1,992,000 after buying an additional 134 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd lifted its position in shares of Eli Lilly and Company by 15.4% during the fourth quarter. Stonehage Fleming Financial Services Holdings Ltd now owns 1,313 shares of the company’s stock worth $1,014,000 after purchasing an additional 175 shares in the last quarter. Finally, Drive Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 8.0% during the fourth quarter. Drive Wealth Management LLC now owns 2,495 shares of the company’s stock worth $1,926,000 after purchasing an additional 185 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LLY shares. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday. Wells Fargo & Company lowered their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $997.22.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $804.87 on Wednesday. The stock has a market cap of $764.08 billion, a P/E ratio of 87.01, a P/E/G ratio of 1.59 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a fifty day moving average price of $778.30 and a two-hundred day moving average price of $847.30. Eli Lilly and Company has a one year low of $637.00 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 12.98 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Eli Lilly and Company declared that its Board of Directors has authorized a stock buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.